

## BIOGRAPHICAL SKETCH - N.I.H. FORMAT / APRIL 2014

NAME Petr Kuzmič	TITLE President, BioKin Ltd.
---------------------	---------------------------------

### EDUCATION

INSTITUTION AND LOCATION	DEGREE	YEAR(S)	FIELD OF STUDY
Institute of Chemical Technology <i>Prague, Czech Republic</i>	M.S.	1979	Medicinal Chemistry
Institute of Organic Chemistry & Biochemistry, Czech Academy of Sciences <i>Prague, Czech Republic</i>	Ph.D.	1984	Physical-Organic Chemistry Bioorganic Chemistry
School of Pharmacy, University of Wisconsin <i>Madison, Wisconsin</i>	Postdoc	1988-9	Bioorganic Chemistry Enzymology

### RESEARCH AND PROFESSIONAL EXPERIENCE

<b>1991-present</b>	<i>President &amp; Owner</i> BioKin, Ltd. – Consulting and Software Development
2014-present	<i>Visiting Scientist</i> Brandeis University – Department of Biology (L. Hedstrom group)
2011-present	<i>Visiting Academic</i> University of Warwick, UK – Molecular Organisation and Assembly in Cells Centre
2001-2002	<i>Lecturer</i> Washington State University, Department of Chemistry
1996-1999	<i>Lecturer</i> University of Wisconsin – Madison, Department of Chemistry
1990-1995	<i>Assistant Scientist</i> University of Wisconsin – Madison, School of Pharmacy
1988-1989	<i>Post-Doctoral Research Associate</i> University of Wisconsin – Madison, School of Pharmacy
1987	<i>Visiting Scholar - National Academy of Sciences U.S.A.</i> University of Wisconsin – Madison, School of Pharmacy
1985-1987	<i>Staff Scientist</i> Institute of Organic Chemistry and Biochemistry – Prague, Czech Republic
1980-1985	<i>Graduate Research Assistant</i> Institute of Organic Chemistry and Biochemistry – Prague, Czech Republic
1977-1979	<i>Research Assistant</i> Institute of Chemical Technology – Prague, Czech Republic

## Consultant

BioKin Ltd. (owned and operated by Dr. Kuzmic as the consultant) has been providing contractual consulting services to US pharmaceutical and biotechnology corporations, usually small-to-medium size. The topics are covered by non-disclosure agreement.

*For example:*

- ArQule, Inc. (Woburn, MA)
- Arris Pharmaceuticals, Inc. (South San Francisco, CA)
- Axys Pharmaceuticals, Inc. (South San Francisco, CA)
- Celera Genomics, Inc. (South San Francisco, CA)
- Chiron Corp. [Novartis] (Emeryville, CA)
- DNAX Research Inst. (Palo Alto, CA)
- Dyax Corp. (Cambridge, MA)
- Hawaii Biotech / Panthera BioPharma (Aiea, HI)
- Phenomix Corp. (San Diego, MA)
- Proteon Therapeutics, Inc. (Waltham, MA)
- Sequoia Pharmaceuticals, Inc. (Gaithersburg, MD)

## Software Developer

Dr. Kuzmic's expertise in enzyme kinetics, assay development, assay optimization, experiment design, and statistical data analysis for drug discovery is embodied in software packages DYNAFIT and BATCHKI. These software packages have been used in hundreds of academic laboratories and numerous corporations.

*For example:*

Amgen	Dyax	Novartis
Anadys	GlaxoSmithKline	Orion
BiogenIDEC	Guilford	Pfizer
BristolMyersSquibb	Hawaii Biotech	Phenomix
Celera Genomics	Millenium	Portola
Chiron	Monsanto	Sequoia
DNAX	Nerviano MedSci	Theravance

## Seminar Speaker

Oral conference presentations and invited lectures or seminars:

Mar 2014 Brandeis University, Waltham, MA  
Jun 2013 Celgene Avilomics Research, Bedford, MA  
Jun 2013 Brandeis University, Waltham, MA  
May 2013 ArQule, Inc., Woburn, MA  
Apr 2013 Novartis Pharmaceuticals, Horsham, U.K.  
Dec 2012 Novartis Pharmaceuticals, Cambridge, MA  
Jul 2012 Novartis Pharmaceuticals, Horsham, U.K.  
Nov 2011 Masaryk University, Brno, Czech Republic  
Apr 2010 Masaryk University, Brno, Czech Republic  
Jul 2009 Max-Planck-Institute for Biomedical Research, Heidelberg  
Jun 2009 *Inhibitors of Protein Kinases* (IPK2009, Warsaw, Poland)  
Sep 2008 University of Dundee, Scotland  
Sep 2008 Czech Academy of Sciences, Prague, Czech Republic  
Jun 2008 Dyax Corp., Cambridge, MA  
Mar 2008 Novartis Pharma, Cambridge, MA  
Jul 2007 Max-Planck-Institute for Biomedical Research, Heidelberg  
Jun 2007 University of Limerick, Ireland  
Mar 2007 Washington State University, Pullman, WA  
Nov 2006 Oregon Health and Science University, Portland, OR  
Dec 2005 University of Montana, Missoula, MT  
Nov 2005 Wayne State University, Detroit, MI  
May 2005 *Steroid Dehydrogenases Workshop* (Schloss Elmau, Germany)  
Dec 2004 Pfizer Inc. (Agouron; La Jolla, CA)  
Sep 2004 *Society for Biomolecular Screening* (SBS10, Orlando, FL)

### Journal Reviewer

- Biochemistry (USA)
- Analytical Biochemistry
- Journal of Theoretical Biology
- Journal of Agricultural and Food Chemistry
- Biochimie
- Enzyme and Microbial Technology

### HONORS

1979 Summa Cum Laude - Institute of Chemical Technology - Prague  
1985 Young Investigator Travel Award - Czech Literary Foundation  
1987 Visiting Scholar - National Academy of Sciences, U.S.A.

## GRANTS

- 2010-14 Masaryk University Lecture Course (“Binding & Kinetics for Experimental Biologists”) - Czech Ministry of Education & The European Union
- 1992 Supercomputer User Access Grant (“Kinetic Mechanism of HIV Proteinase Inhibition”) - U.W. Graduate School and San Diego Supercomputer Center
- 1990 Institutional Research Grant (“Artificial Intelligence System for the Evaluation of Antifolate Activity”) - American Cancer Society

## PROFESSIONAL SOCIETIES

- 2013-present Biochemical Society (London)
- 1990-present American Chemical Society
- 1990-present American Association for the Advancement of Science

## PUBLICATIONS

- [1] Schwartz, P. A., Kuzmič, P., Solowiej, J., Bergqvist, S., Bolanos, B., Almaden, C., Nagata, A., Ryan, K., Feng, J., Dalvie, D., Kath, J., Xu, M., Wani, R., and Murray, B. W. (2014) Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance. *Proc. Nat. Acad. Sci. U.S.A.* **111**, 173178.
- [2] Kleckner, I. R., McElroy, C. A., Kuzmič, P., Gollnick, P., , and Foster, M. P. (2013) Homotropic cooperativity from the activation pathway of the allosteric ligand-responsive regulatory trp RNA-binding attenuation protein. *Biochemistry* **52**, 8855–8865.
- [3] Salykin, A., Kuzmič, P., Kyrylenko, O., Musilová, J., Glatz, Z., Dvořák, P., and Kyrylenko, S. (2013) Nonlinear regression models for determination of nucleotide content in human embryonic stem cell lysates. *Stem Cell Rev. Rep.* **9**, 786793.
- [4] Kuzmič, P. (2011) Optimal design for the dose-response screening of tight-binding enzyme inhibitors. *Anal. Biochem.* **419**, 117–122.
- [5] Rothnie, A., Clarke, A. R., Kuzmič, P., Cameron, A., and Smith, C. J. (2011) A sequential mechanism for clathrin cage disassembly by 70-kDa heat-shock cognate protein (Hsc70) and auxilin. *Proc. Nat. Acad. Sci. U.S.A.* **108**, 6927–6932.
- [6] Kuzmič, P. (2010) A generalized numerical approach to steady-state enzyme kinetics: Applications to protein kinase inhibition. *Biochim. Biophys. Acta* **1804**, 635–641.
- [7] Clé, C., Martin, C., Field, R. A., Kuzmič, P., and Bornemann, S. (2010) Detection of enzyme-catalyzed polysaccharide synthesis on surfaces. *Biocatal. Biotrans.* **28**, 64–71.
- [8] Kuzmič, P. (2009) DYNAFIT – A software package for enzymology. *Meth. Enzymol.* **467**, 247–280.

- [9] Sexton, D. J., Chen, T., Martik, D., Kuzmič, P., Kuang, G., Chen, J., Nixon, A. E., Zuraw, B. L., Forteza, R. M., Abraham, W. M., and Wood, C. R. (2009) Specific inhibition of tissue kallikrein 1 with a human monoclonal antibody reveals a potential role in airway diseases. *Biochem. J.* **422**, 383–392.
- [10] Kuzmič, P. (2009) Application of the Van Slyke–Cullen irreversible mechanism in the analysis of enzymatic progress curves. *Anal. Biochem.* **394**, 287–289.
- [11] Kuzmič, P., Lorenz, T., and Reinstein, J. (2009) Analysis of residuals from enzyme kinetic and protein folding experiments in the presence of correlated experimental noise. *Anal. Biochem.* **395**, 1–7.
- [12] Gasa, T. B., Spruell, J. M., Dichtel, W. R., Sorensen, T. J., Philp, D., Stoddart, J. F., and Kuzmič, P. (2009) Complexation between methyl viologen (Paraquat) bis(hexafluorophosphate) and dibenzo[24]crown-8 revisited. *Chem. Eur. J.* **15**, 106–116.
- [13] Kuzmič, P. (2008) A steady state mathematical model for stepwise “slow-binding” reversible enzyme inhibition. *Anal. Biochem.* **380**, 5–12.
- [14] Collom, S. L., Laddusaw, R. M., Burch, A. M., Kuzmič, P., Perry, M. D., and Miller, G. P. (2008) CYP2E1 substrate inhibition: Mechanistic interpretation through an effector site for monocyclic compounds. *J. Biol. Chem.* **283**, 3487–3496.
- [15] Kona, F., Xu, X., Martin, P., Kuzmic, P., and Gatti, D. L. (2007) Structural and mechanistic changes along an engineered path from metallo to nonmetallo 3-deoxy-D-manno-octulosonate 8-phosphate synthases. *Biochemistry* **46**, 4532–4544.
- [16] Jamakhandi, A. P., Kuzmič, P., Sanders, D. E., and Miller, G. P. (2007) Global analysis of protein-protein interactions reveals multiple CYP2E1–reductase complexes. *Biochemistry* **46**, 10192–10201.
- [17] Urbina, H. D., Debaene, F., Jost, B., Bole-Feysot, C., Mason, D. E., Kuzmič, P., Harris, J. L., and Winssinger, N. (2006) Self-assembled small-molecule microarrays for protease screening and profiling. *ChemBioChem* **7**, 1790–1797.
- [18] Kuzmič, P., Millis, S., Cregar, L., and Goldman, M. (2006) Mixed-type noncompetitive inhibition of anthrax Lethal Factor protease by aminoglycosides. *FEBS J.* **273**, 3054 – 3062.
- [19] Kuzmič, P. (2006) A generalized numerical approach to rapid-equilibrium enzyme kinetics: Application to 17 $\beta$ -HSD. *Mol. Cell. Endocrinol.* **248**, 172–181.
- [20] Tang, C., Simo, O., O’Malley, S., Nagata, M., Goldman, M., Cregar, L., Nguyen, D., Kuzmič, P., Moayeri, M., Leppla, S., Liddington, R., Hemscheidt, T., and Jiao, G. S. (2004) Discovery of cationic inhibitors of anthrax Lethal Factor protease. *Abstr. Pap. Am. Chem. Soc.* **228**, U967 – U968.
- [21] Goldman, M., Cregar, L., Nguyen, D. T., Kuzmič, P., Moyaeri, M., Leppla, S. H., Wong, T. Y., Liddington, R. C., Simo, O., O’Malley, S., Nagata, M., Jiao, G.-S., Hemscheidt, T. K., and Tang, C. (2004) Discovery and characterization of cationic inhibitors of anthrax Lethal Factor protease. *Poster No. P01008, Society for Biomolecular Screening Annual Conference, Orlando, September 11-15, 2004.*
- [22] Chu, D., Bungiro, R. D., Ibanez, M., Harrison, L. M., Campodonico, E., Jones, B. F., Mieszczynek, J., Kuzmič, P., and Cappello, M. (2004) Molecular characterization of *Ancylostoma ceylanicum* Kunitz-type serine protease inhibitor: Evidence for a role in hookworm-associated growth delay. *Infect. Immun.* **72**, 2214 – 2221.

- [23] Williams, C. R., Snyder, A. K., Kuzmič, P., O'Donnell, M., and Bloom, L. B. (2004) Mechanism of loading the Escherichia coli DNA polymerase III sliding clamp - I. Two distinct activities for individual ATP sites in the gamma complex. *J. Biol. Chem.* **279**, 4376 – 4385.
- [24] Kuzmič, P., Hill, C., and Janc, J. W. (2004) Practical robust fit of enzyme inhibition data. *Methods Enzymol.* **383**, 366 – 381.
- [25] Kuzmič, P., Hill, C., Kirtley, M. P., and Janc, J. W. (2003) Kinetic determination of tight-binding impurities in enzyme inhibitors. *Anal. Biochem.* **319**, 272 – 279.
- [26] Lake-Bakaar, G., Ruffini, L., and Kuzmič, P. (2003) Effect of Ribavirin and Amantadine on early hepatitis C virus RNA rebound and clearance in serum during daily high-dose interferon. *Dig. Dis. Sci.* **48**, 126 – 139.
- [27] Ahn, J., Won, T. W., Kaplan, D. E., Londin, E. R., Kuzmič, P., Gelernter, J., and Gruen, J. R. (2002) A detailed physical map of the 6p reading disability locus, including new markers and confirmation of recombination suppression. *Hum. Genet.* **111**, 339 – 349.
- [28] Harrison, L. M., Nerlinger, A., Bungiro, R. D., Cordova, J. L., Kuzmič, P., and Cappello, M. (2002) Molecular characterization of Ancylostoma inhibitors of coagulation factor Xa - Hookworm anticoagulant activity in vitro predicts parasite bloodfeeding in vivo. *J. Biol. Chem.* **277**, 6223 – 6229.
- [29] Lake-Bakaar, G., Ruffini, L., and Kuzmič, P. (2001) The effect of combining interferon, Ribavirin and Amantadine on hepatitis C viral dynamics: Further evidence that Ribavirin and Amantadine block de novo re-infection. *Gastroenterology* **120**, A29.
- [30] Kuzmič, P., Elrod, K. C., Cregar, L. M., Sideris, S., Rai, R., and Janc, J. W. (2000) High-throughput screening of enzyme inhibitors: Simultaneous determination of tight-binding inhibition constants and enzyme concentration. *Anal. Biochem.* **286**, 45 – 50.
- [31] Kuzmič, P., Sideris, S., Cregar, L. M., Elrod, K. C., Rice, K. D., and Janc, J. W. (2000) High-throughput screening of enzyme inhibitors: Automatic determination of tight-binding inhibition constants. *Anal. Biochem.* **281**, 62 – 67.
- [32] Lake-Bakaar, G. V., Ruffini, L., and Kuzmič, P. (2000) HCV viral dynamics during therapy with high dose interferon-A-2B plus or minus Ribavirin: Correlation with ALT suggests Ribavirin may suppress early de novo re-infection. *Gastroenterology* **118**, A1016.
- [33] Lake-Bakaar, G. V., Ruffini, L., and Kuzmič, P. (2000) Dynamics of HLA-1 Beta-2-microglobulin subunit during treatment with high dose interferon with or without Ribavirin: Correlation with serum HCV RNA and ALT. *Gastroenterology* **118**, A940.
- [34] Lake-Bakaar, G., Ruffini, L., and Kuzmič, P. (2000) Early HCV RNA 'rebound' during daily high dose interferon treatment: Inhibition by Ribavirin. *Gastroenterology* **118**, A946.
- [35] Milstone, A. M., Harrison, L. M., Bungiro, R. D., Kuzmič, P., and Cappello, M. (2000) A broad spectrum Kunitz type serine protease inhibitor secreted by the hookworm Ancylostoma ceylanicum. *J. Biol. Chem.* **275**, 29391 – 29399.
- [36] Kuzmič, P. (1999) General numerical treatment of competitive binding kinetics: Application to thrombin-dehydrothrombin-hirudin. *Anal. Biochem.* **267**, 17 – 23.

- [37] Kuzmič, P. (1998) Fixed-point methods for computing the equilibrium composition of complex biochemical mixtures. *Biochem. J.* **331**, 571 – 575.
- [38] Kuzmič, P., Peranteau, A. G., García-Echeverría, C., and Rich, D. H. (1996) Mechanical effects on the kinetics of the HIV proteinase deactivation. *Biochem. Biophys. Res. Commun.* **221**, 313 – 317.
- [39] Moss, M. L., Kuzmič, P., Stuart, J. D., Tian, G. C., Peranteau, A. G., Frye, S. V., Kadwell, S. H., Kost, T. A., Overton, L. K., and Patel, I. R. (1996) Inhibition of human steroid  $5\alpha$  reductases type I and II by 6-aza-steroids: Structural determinants of one-step vs. two-step mechanism. *Biochemistry* **35**, 3457 – 3464.
- [40] Kuzmič, P. (1996) Program DYNAFIT for the analysis of enzyme kinetic data: Application to HIV proteinase. *Anal. Biochem.* **237**, 260 – 273.
- [41] Peranteau, A. G., Kuzmič, P., Angell, Y., García-Echeverría, C., and Rich, D. H. (1995) Increase in fluorescence upon the hydrolysis of tyrosine peptides: Application to proteinase assays. *Anal. Biochem.* **227**, 242 – 245.
- [42] Kuzmič, P. (1993) Kinetic assay for HIV proteinase subunit dissociation. *Biochem. Biophys. Res. Commun.* **191**, 998 – 1003.
- [43] Kuzmič, P., García-Echeverría, C., and Rich, D. H. (1993) Stabilization of HIV proteinase dimer by bound substrate. *Biochem. Biophys. Res. Commun.* **194**, 301 – 305.
- [44] García-Echeverría, C., Kofron, J. L., Kuzmič, P., and Rich, D. H. (1993) A continuous spectrophotometric direct assay for peptidyl prolyl *cis-trans* isomerases. *Biochem. Biophys. Res. Commun.* **191**, 70 – 75.
- [45] Rich, D. H., Kofron, J., Kishore, V., Kuzmič, P., García-Echeverría, C., Fesik, S. W., and Gemmecker, G. (1992) Effect of lithium-chloride on conformational equilibria in peptidyl prolyl *cis-trans* isomerase substrates and inhibitors. *Abstr. Pap. Am. Chem. Soc.* **203**, 149.
- [46] Moss, M. L., Palmer, R. E., Kuzmič, P., Dunlap, B. E., Henzel, W., Kofron, J. L., Mellon, W. S., Royer, C. A., and Rich, D. H. (1992) Identification of actin and *hsp-70* as Cyclosporine-A binding-proteins by photoaffinity-labeling and fluorescence displacement assays. *J. Biol. Chem.* **267**, 22054 – 22059.
- [47] García-Echeverría, C., Kofron, J. L., Kuzmič, P., Kishore, V., and Rich, D. H. (1992) Continuous fluorometric direct (uncoupled) assay for peptidyl prolyl *cis-trans* isomerases. *J. Am. Chem. Soc.* **114**, 2758 – 2759.
- [48] Kuzmič, P., Moss, M. L., Kofron, J. L., and Rich, D. H. (1992) Fluorescence displacement method for the determination of receptor ligand-binding constants. *Anal. Biochem.* **205**, 65 – 69.
- [49] Kuzmič, P., Ng, K. Y., and Heath, T. D. (1992) Mixtures of tight-binding enzyme-inhibitors – Kinetic analysis by a recursive rate-equation. *Anal. Biochem.* **200**, 68 – 73.
- [50] Kofron, J. L., Kuzmič, P., Kishore, V., Gemmecker, G., Fesik, S. W., and Rich, D. H. (1992) Lithium-chloride perturbation of *cis-trans* peptide-bond equilibria: Effect on conformational equilibria in Cyclosporine-A and on time-dependent inhibition of cyclophilin. *J. Am. Chem. Soc.* **114**, 2670 – 2675.

- [51] Kofron, J. L., Kuzmič, P., Kishore, V., Colonbonilla, E., and Rich, D. H. (1991) Determination of kinetic constants for peptidyl prolyl *cis-trans* isomerases by an improved spectrophotometric assay. *Biochemistry* **30**, 6127 – 6134.
- [52] Kuzmič, P., Sun, C. Q., Zhao, Z. C., and Rich, D. H. (1991) Long-range electrostatic effects in pepsin catalysis. *Tetrahedron* **47**, 2519 – 2534.
- [53] Kuzmič, P., Sun, C.-Q., Zhao, Z.-C., and Rich, D. H. (1991) Nonspecific electrostatic binding of substrates and inhibitors to porcine pepsin. *Adv. Experim. Med. Biol.* **306**, 75 – 86.
- [54] Kuzmič, P., Sun, C. Q., and Rich, D. H. (1990) Benzophenone analogs of pepstatin A and Cyclosporin A as potential photoaffinity labeling reagents. In *Peptides - Chemistry, Structure and Biology*, Rivier, J. E. and Marshall, G. R., editors, 129 – 131. ESCOM, Leiden.
- [55] Kuzmič, P. and Souček, M. (1986) Photo-cyanation of 3,4-di-methoxy-1-nitro-benzene. A quantitative study. *Collect. Czech. Chem. Commun.* **51**, 358 – 367.
- [56] Kuzmič, P., Pavlíčková, L., and Souček, M. (1986) Photochemical hydrolysis of some nitrophenyl acetates. *Collect. Czech. Chem. Commun.* **51**, 1293 – 1300.
- [57] Kuzmič, P. and Souček, M. (1987) Substituent effects in aromatic photochemistry. UV irradiation of 3,4-dimethoxybenzotrile and 3,4-dimethoxyacetophenone in the presence of inorganic anions. *Collect. Czech. Chem. Commun.* **52**, 980 – 988.
- [58] Kuzmič, P., Pavlíčková, L., and Souček, M. (1987) Photoreaction of N-butyl 3,4-dimethoxy-6-nitrobenzamide with butylamine. A model study for lysine-directed photoaffinity labeling. *Collect. Czech. Chem. Commun.* **52**, 1780 – 1785.
- [59] Urban, J., Kuzmič, P., Šaman, D., and Souček, M. (1987) Regioselectivity of nucleophilic aromatic photosubstitution in the biphenyl series. Photohydrolysis of some dimethoxynitrobiphenyls. *Collect. Czech. Chem. Commun.* **52**, 2482 – 2491.
- [60] Pavlíčková, L., Kuzmič, P., and Souček, M. (1986) Chemical actinometry in the UV range based on the photohydrolysis of 3,4-dimethoxy-1-nitro benzene. *Collect. Czech. Chem. Commun.* **51**, 368 – 374.
- [61] Kuzmič, P., Pavlíčková, L., Velek, J., and Souček, M. (1986) Photoreaction of 3,4-dimethoxy-1-nitrobenzene with butylamine. A pH dependence of regioselectivity. *Collect. Czech. Chem. Commun.* **51**, 1665 – 1670.
- [62] Dědek, V., Liška, F., Fikar, J., and Kuzmič, P. (1985) Free-radical induced reduction of C-Cl bonds in chlorofluoroethers by alcohols and ethers. *J. Fluorine Chem.* **29**, 152.
- [63] Liška, F., Fikar, J., and Kuzmič, P. (1993) Radical reduction of C-Cl bonds in chlorofluoro ethers. *Collect. Czech. Chem. Commun.* **58**, 565 – 574.
- [64] Dědek, V., Liška, F., Kuzmič, P., Fikar, J., Vesely, I., Pavlovská, E., and Simon, J. (1988) Preparation of 2-chloro-1,1,2-trifluoroethyl dichloromethyl ether as an inhalation anesthetic intermediate. *Czech. Pat. CS 237,733; Chem. Abstr. 166971.*
- [65] Dědek, V., Liška, F., Fikar, J., Kuzmič, P., Pavlovská, E., Salamon, M., and Simon, J. (1988) Purification of 2-chloro-1,1,2-trifluoroethyl dichloromethyl ether as an inhalation anesthetic intermediate. *Czech. Pat. CS 237,734; Chem. Abstr. 166972.*